ReviewDrug delivery and translational research2025
Clinical translation and landscape of silver nanoparticles.
Review in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Protective mechanisms and therapeutic promise of nanomaterials in radiation-induced diseases.International journal of pharmaceutics: X · 2026Review
- Clinical translation and landscape of copper nanoparticles.Drug delivery and translational research · 2026Review
- Clinical translation and landscape of stimuli-responsive nanomedicines and microscale therapeutics.Chemical Society reviews · 2026Review
- Hype vs. Health: How Approved Nanomedicines Have Met (or Missed) Early Predictions.Nanomaterials (Basel, Switzerland) · 2026Article
- The application of metal nanomaterials in cancer diagnosis and treatment.Discover nano · 2026Review
- UV-Assisted Silver Functionalization of Cotton Gauze for Antimicrobial and Biocompatible Wound Healing Applications.Microorganisms · 2026Article
- Metal Nanoparticles as Sensitizers in Energy-Based Therapies for Lung Cancer: From Mechanistic Insights to Clinical Translation.International journal of nanomedicine · 2026Review
- Silver Nanoparticles Templated by the M13 Phage Exhibit High Antibacterial Activity against Gram-Negative Pathogens and a Reduced Rate of Bacterial Resistance In Vitro.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Silver integrated hybrids and nanocomposites for next-generation biomedicine: Beyond antimicrobial coatings toward smart sense-response-heal platforms.Materials today. Bio · 2025Review
- Understanding the action mechanisms and safety of nanoparticles with functional toxicogenomics.Nanomedicine (London, England) · 2025Article
- Green Synthesis of Silver Nanoparticles and Polymeric Nanofiber Composites: Fabrications, Mechanisms, and Applications.Polymers · 2025Review
- Recent Advances in the Application of Silver Nanoparticles for Enhancing Phototherapy Outcomes.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Silver Nanoparticle-Mediated Antiviral Efficacy against Enveloped Viruses: A Comprehensive Review.Global challenges (Hoboken, NJ) · 2025Review
- Improving heat resilience in fattening rabbits: nutritional strategies for mitigation via regulating blood physiology, inflammation and antioxidant pathways.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite being clinically used for over a century, the benefits of silver nanoparticles are perennially under debate and dispute. In the last two decades, a revived interest in their therapeutic applications has resulted in a few new formulations transitioning into clinical trials. These metal nanomedicines are used in concrete applications that are defined by the physicochemical and biological features of the silver nanoconstructs, as well as their biodistribution profiles. Examples of these applications are topical antibacterial and antiviral therapies and wound healing, as these avoid concerns regarding the long-term accumulation of the nanomedicines in fenestrated organs after intravenous administration. Here, we discuss the current landscape of silver nanoparticles, and critically analyze the characteristics that endowed their transition and use in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.